The medico-legal significance of pharmacokinetic interactions with ethanol

被引:3
|
作者
Langford, N. J. [1 ]
Ferner, R. E. [2 ]
机构
[1] Leicester Royal Infirm, Leicester LE1 5WW, Leics, England
[2] Univ Birmingham, Dept Clin Pharmacol, Birmingham B15 2TT, W Midlands, England
关键词
LIVER ALCOHOL DEHYDROGENASE; 1ST PASS METABOLISM; BLOOD-ALCOHOL; RANITIDINE INCREASES; CHLORAL HYDRATE; HUMANS; PERFORMANCE; ABSORPTION; INTOXICATION; ELIMINATION;
D O I
10.1258/msl.2012.012069
中图分类号
D9 [法律]; DF [法律];
学科分类号
0301 ;
摘要
In the UK, the maximal permitted ethanol concentration for driving is 80 mg ethanol/100 mL blood, 35 g ethanol/100 mL breath or 107 mg ethanol/100 mL urine. Drivers exceeding the prescribed limit face severe penalties, which they are often anxious to avoid, either by acquittal or by putting forward special reasons' why they should not be disqualified from driving. One frequently explored defence is that the accused was taking prescribed medication. Defence solicitors often ask the question whether the prescribed medication could have caused significantly altered blood ethanol concentrations. This paper reviews the impact of various medications and how they can influence the blood ethanol concentration. Although many drugs can interact with ethanol at a pharmacodynamic level, causing increased impairment, relatively few drugs interact with ethanol pharmacokinetically leading to significantly altered blood ethanol concentrations.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 50 条
  • [41] Metabolism and drug interactions of Korean ginseng based on the pharmacokinetic properties of ginsenosides: Current status and future perspectives
    Park, Jong Dae
    JOURNAL OF GINSENG RESEARCH, 2024, 48 (03) : 253 - 265
  • [42] Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults
    Nakamaru, Yoshinobu
    Hayashi, Yoshiharu
    Davies, Martin
    Heuer, Horst Juergen
    Hisanaga, Noriko
    Akimoto, Kei
    CLINICAL THERAPEUTICS, 2015, 37 (09) : 2007 - 2018
  • [43] Optimal Administration of Glycyrrhizin Avoids Pharmacokinetic Interactions With High-dose Methotrexate and Exerts a Hepatoprotective Effect
    Mano, Yasunari
    Abe, Kentaro
    Takahashi, Mio
    Higurashi, Tsukasa
    Kawano, Yohei
    Miyazaki, Satoru
    Maeda-Minami, Ayako
    ANTICANCER RESEARCH, 2023, 43 (04) : 1493 - 1501
  • [44] Excipient-drug pharmacokinetic interactions: Effect of disintegrants on efflux across excised pig intestinal tissues
    Gerber, Werner
    Hamman, Josias H.
    Steyn, Johan D.
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2018, 26 : S115 - S124
  • [45] Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects
    Jeon, Ji-Young
    Kim, Sun-Young
    Moon, Seol Ju
    Oh, Kyeongmin
    Lee, Jiwon
    Kim, Bongtae
    Song, Geun Seog
    Kim, Min-Gul
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 722 - 734
  • [46] Clozapine-Induced Severe Toxicity: Exploring the Pharmacokinetic Profile of Clozapine and Its Significance in Hemodynamic Instability - A Case Report
    Yu, Zhu-Xi
    Pi, Yang
    Chen, Mei-Kai
    Dong, Dan-Jiang
    Gu, Qin
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2024, 17 : 111 - 120
  • [47] INTERACTIONS BETWEEN STUDENTS AND TUTOR IN PROBLEM-BASED LEARNING: THE SIGNIFICANCE OF DEEP LEARNING
    Azer, Samy A.
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2009, 25 (05) : 240 - 249
  • [48] Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions
    Jing, Jing
    Nelson, Cara
    Paik, Jisun
    Shirasaka, Yoshiyuki
    Amory, John K.
    Isoherranen, Nina
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 361 (02) : 246 - 258
  • [49] Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
    Xu, Ruijuan
    Ge, Weihong
    Jiang, Qing
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (06) : 755 - 765
  • [50] Pharmacokinetic Interactions Between the Orexin Receptor Antagonist Almorexant and the CYP3A4 Inhibitors Ketoconazole and Diltiazem
    Dingemanse, Jasper
    Cruz, Hans Gabriel
    Gehin, Martine
    Hoever, Petra
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (05) : 1548 - 1556